Short answer
Alnylam Pharmaceuticals (ALNY) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026.
Alnylam Pharmaceuticals Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q1 product revenue $1.036B: AMVUTTRA $889.9M, ONPATTRO $20.5M, GIVLAARI $74.4M, OXLUMO $51.3M
- Best performer AMVUTTRA $889.9M; weakest ONPATTRO $20.5M
- TRITON-CM enrollment expanded from 1,250 to approximately 1,750 patients
- 2028 Notes issuance $661.3M; capped-call payments $35.3M
- Management targeting nucresiran ATTR-CM launch by 2030, assuming positive data and regulatory approval
Risk Factors
- New regulatory risk triggered by AMVUTTRA’s March 2025 FDA approval for ATTR-CM and expanded global commercialization
- AMVUTTRA concentration risk with $1.04 billion in first-quarter 2026 product revenue
- Regulatory pricing risk from potential U.S. drug-price negotiation, most-favored-nation measures, and disclosure requirements
- Liquidity risk from $3.01 billion in cash, equivalents, and marketable securities exposed to credit, interest-rate, and market-value losses
- Leqvio royalty concentration risk if Blackstone receives under $1.00 billion by December 31, 2029, increasing its share to 55%
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Alnylam Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.